This company listing is no longer active
SciClone Pharmaceuticals (Holdings) Past Earnings Performance
Past criteria checks 6/6
SciClone Pharmaceuticals (Holdings) has been growing earnings at an average annual rate of 11.2%, while the Pharmaceuticals industry saw earnings growing at 6% annually. Revenues have been growing at an average rate of 14.8% per year. SciClone Pharmaceuticals (Holdings)'s return on equity is 34.4%, and it has net margins of 35.6%.
Key information
11.2%
Earnings growth rate
7.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 14.8% |
| Return on equity | 34.4% |
| Net Margin | 35.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings
Apr 02
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today
Dec 14Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Jun 19SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's
May 31Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Feb 17Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Dec 02We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings
Oct 04SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jul 27An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued
Jun 02Revenue & Expenses Breakdown
How SciClone Pharmaceuticals (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,156 | 1,122 | 870 | 171 |
| 30 Sep 23 | 3,017 | 1,038 | 839 | 159 |
| 30 Jun 23 | 2,878 | 953 | 808 | 147 |
| 31 Mar 23 | 2,814 | 904 | 781 | 135 |
| 31 Dec 22 | 2,750 | 855 | 753 | 124 |
| 30 Sep 22 | 2,706 | 844 | 738 | 134 |
| 30 Jun 22 | 2,662 | 833 | 724 | 145 |
| 31 Mar 22 | 2,590 | 878 | 726 | 140 |
| 31 Dec 21 | 2,518 | 923 | 729 | 134 |
| 30 Sep 21 | 2,259 | 837 | 742 | 114 |
| 30 Jun 21 | 2,089 | 779 | 753 | 85 |
| 31 Mar 21 | 2,004 | 766 | 703 | 80 |
| 31 Dec 20 | 1,919 | 754 | 653 | 75 |
| 30 Sep 20 | 2,001 | 817 | 615 | 77 |
| 31 Dec 19 | 1,708 | 615 | 579 | 88 |
| 31 Dec 18 | 1,409 | 535 | 533 | 77 |
| 31 Dec 17 | 1,213 | 20 | 728 | 83 |
| 30 Jun 17 | 1,166 | 294 | 586 | 96 |
| 31 Mar 17 | 1,146 | 258 | 587 | 111 |
| 31 Dec 16 | 1,112 | 213 | 591 | 105 |
| 30 Sep 16 | 1,060 | 246 | 544 | 88 |
| 30 Jun 16 | 1,072 | 257 | 550 | 72 |
| 31 Mar 16 | 1,034 | 183 | 515 | 82 |
| 31 Dec 15 | 1,021 | 191 | 509 | 80 |
| 30 Sep 15 | 991 | 130 | 488 | 129 |
| 30 Jun 15 | 913 | 102 | 458 | 124 |
| 31 Mar 15 | 879 | 186 | 442 | 88 |
| 31 Dec 14 | 836 | 156 | 426 | 90 |
| 30 Sep 14 | 774 | 133 | 429 | 29 |
| 30 Jun 14 | 790 | 140 | 467 | 28 |
| 31 Mar 14 | 770 | 68 | 499 | 57 |
| 31 Dec 13 | 769 | 66 | 510 | 49 |
| 30 Sep 13 | 780 | 78 | 541 | 35 |
Quality Earnings: 6600 has high quality earnings.
Growing Profit Margin: 6600's current net profit margins (35.6%) are higher than last year (31.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6600's earnings have grown by 11.2% per year over the past 5 years.
Accelerating Growth: 6600's earnings growth over the past year (31.2%) exceeds its 5-year average (11.2% per year).
Earnings vs Industry: 6600 earnings growth over the past year (31.2%) exceeded the Pharmaceuticals industry -1%.
Return on Equity
High ROE: 6600's Return on Equity (34.4%) is considered high.